NEPT - Neptune Technologies & Bioressources Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.48
+0.28 (+8.75%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.20
Open3.24
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.21 - 3.53
52 Week Range0.70 - 3.53
Volume1,909,187
Avg. Volume751,993
Market Cap269.019M
Beta0.90
PE Ratio (TTM)52.73
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2008-07-24
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.comlast month

    [$$] 5 Biotech Stocks a Pro Is Buying

    Joseph Edelman, the founder of Perceptive Advisors and its hedge fund, Perceptive Life Sciences, managed to secure a nearly 4% gain in 2016’s rout. Perceptive now owns 3.4 million shares of La Jolla, a 15.3% stake, up from 2.2 million shares, or 9.7%, at Sept. 30.

  • TheStreet.comlast month

    Anyone Who Resists the Rise of Legal Cannabis Is Among Dumbest on Wall Street

    You don't have to be a stoner to realize that legal cannabis is an industry ripe for profit. Here are two companies that could profit from a push into the legal weed game.

  • Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q2, 2018 By the Numbers : November 30, 2017
    Capital Cube2 months ago

    Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q2, 2018 By the Numbers : November 30, 2017

    Categories: Yahoo FinanceGet free summary analysis Neptune Technologies & Bioresources, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neptune Technologies & Bioresources, Inc. – Cipher Pharmaceuticals Inc., Novelion Therapeutics Inc. and ChromaDex Corporation (CPH-CA, NVLN-US and CDXC-US) that have also reported for this period. ... Read more (Read more...)

  • Neptune Technologies & Bioresources, Inc.: Price momentum supported by strong fundamentals
    Capital Cube2 months ago

    Neptune Technologies & Bioresources, Inc.: Price momentum supported by strong fundamentals

    Categories: Yahoo FinanceNeptune Technologies & Bioresources, Inc. relative valuation is NEUTRAL and it has a fundamental analysis score of 63. Our analysis is based on comparing Neptune Technologies & Bioresources, Inc. with the following peers – Cipher Pharmaceuticals Inc., Novelion Therapeutics Inc., TerraVia Holdings, Inc. and ChromaDex Corporation (CPH-CA, NVLN-US, TVIAQ-US and CDXC-US). Neptune Technologies & Bioresources, ... Read more (Read more...)

  • Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017
    Capital Cube4 months ago

    Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Neptune Technologies & Bioresources, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Neptune Technologies & Bioresources, Inc. – Cipher Pharmaceuticals Inc., Novelion Therapeutics Inc. and ChromaDex Corporation (CPH-CA, NVLN-US and CDXC-US) that have also reported for this period. ... Read more (Read more...)

  • Neptune Technologies & Bioresources, Inc.: Price momentum supported by strong fundamentals
    Capital Cube5 months ago

    Neptune Technologies & Bioresources, Inc.: Price momentum supported by strong fundamentals

    Categories: Yahoo FinanceNeptune Technologies & Bioresources, Inc. relative valuation is NEUTRAL and it has a fundamental analysis score of 72. Our analysis is based on comparing Neptune Technologies & Bioresources, Inc. with the following peers – Novelion Therapeutics Inc., Cipher Pharmaceuticals Inc., EcoSynthetix Inc. and TerraVia Holdings, Inc. (NVLN-US, CPH-CA, ECSNF-US and TVIAQ-US). Neptune Technologies & Bioresources, ... Read more (Read more...)